jennifer good md hospice medical director, home nursing agency altoona, pennsylvania mary mihalyo...
TRANSCRIPT
![Page 1: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/1.jpg)
Jennifer Good MDHospice Medical Director, Home Nursing
AgencyAltoona, Pennsylvania
Mary Mihalyo BS, PharmD, RPhDuquesne University
Pittsburgh , Pennsylvania
![Page 2: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/2.jpg)
ObjectivesTo understand that many medications that
patients are on for chronic illnesses may not be helpful late in life.
To understand that decisions for discontinuation must be individualized and take into consideration the patient’s goals of therapy, life expectancy and risk/benefits of discontinuation (will depend on comorbidities).
To understand that there is little experimental data dictating discontinuing medications in palliative care patients.
![Page 3: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/3.jpg)
Elizabeth N.Elizabeth N. is a 90 y/o woman who has been referred
to hospice following three hospitalizations in the last 2 months for refractory congestive heart failure. She is short of breath with minimal exertion. She has decided that she does not want to be readmitted to the hospital.
Her current medications include furosemide, lisinopril, carvedilol, spironolactone, warfarin, simvastatin, ASA, alendronate and morphine sulfate PRN.
Would it be appropriate to discontinue any of these medications?
![Page 4: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/4.jpg)
Specific considerations in discontinuing medicationsLife-expectancy
What is patient’s life expectancy?How long does it take to see a benefit from a
given drug?Risk/benefit ratios
For general populationFor given patient
Patient’s goals of therapyTreatment targets (what is the treatment for)
![Page 5: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/5.jpg)
Life-expectancy?Palliative Care vs. Hospice Care
Expected life expectancy in hospice is < 6 months
Expected life expectancy in palliative patients with multiple chronic co-morbidities might be 12 months or more
![Page 6: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/6.jpg)
How long to see effect from prescribed medication?How long does it take for medication to
render effect?Analgesics—minutes to hoursBisphosph0nates for osteoporosis—months to
yearsTight glucose control in DM—yearsStatins?
![Page 7: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/7.jpg)
Risk-benefit ratio?Benefits for general population
NNTBenefits for given patient
Controls symptomsHarms for general population
NNHHarms for a given patient
Adverse drug reactionsCostTreatment is not in line with overall goals of
care
![Page 8: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/8.jpg)
Patient’s goals of therapy?Prolong lifePrevent morbiditySlow disease progressionPrevent declineComfort
![Page 9: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/9.jpg)
Treatment targets?Primary preventionSecondary preventionControl chronic diseasesTreat acute diseasesControl symptoms
![Page 10: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/10.jpg)
Medications to consider discontinuingCholesterol lowering therapyAnti-platelet agentsAnti-coagulantsDementia medicationsOsteoporosis medications
![Page 11: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/11.jpg)
Discontinuing statinsWhat is risk of ACS or CVA upon
discontinuing?ACS
Prevent 5 MIs in 100 patients treated for 5 years (secondary prevention)
Decreased risk of death by 20 – 30% over 5 years Patients have increased mortality if statin
discontinued during ACS (5% vs. 11%) Immediate risk reduction—1 less MI in 100 patients
treated for one month after MI.CVA
![Page 12: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/12.jpg)
Recommendations for discontinuing statinContinue:
Recent MIRecent CVA? Symptoms of myocardial ischemia
Discontinue:Patients on statin for primary prophylaxis
![Page 13: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/13.jpg)
Anti-platelet AgentsAspirin
Clopidogrel (Plavix ®)/Prasugrel (Effient®)
ASA/Dipyridamole (Aggrenox ®)
![Page 14: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/14.jpg)
Discontinuing anti-platelet agentsContinue clopidogrel/ASA if:
Bare metal stent in last 3 monthsDrug-eluting stent in last 12 monthsRecent TIA/CVA (if occurred while patient on ASA)
Continue Aggrenox® if:Recent TIA/CVA (if occurred while patient on ASA)
Continue ASA if:Used for secondary prevention in patients with h/o
ACS or CVAUsed for primary prevention in high risk patientRecommend 81 mg/d
![Page 15: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/15.jpg)
AnticoagulantsWarfarin—most common indications:
Chronic Atrial Fibrillation to prevent thromboembolic complications
Mechanical heart valves to prevent valve thrombosis and thromboembolic complications
Patients with history of venous thromboemboli (VTE)
Dabigatran—a new oral direct thrombin inhibitorNon-valvular chronic Atrial Fibrillation
Low molecular weight heparinsMost commonly used long term in patients with
VTE and concomitant malignancy
![Page 16: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/16.jpg)
Risk of Embolic Events in AFRisk is 2 – 18% yearRisk based on
CHAD2 score:Low risk = 0Moderate = 1 High risk= ≥ 2
CHAD2 Score Stroke Risk %)1
0 1.9
1 2.8
2 4.0
3 5.9
4 8.5
5 12.5
6 18.5
1 Gage BF. JAMA 285(22):2864 – 70.
![Page 17: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/17.jpg)
Recommendation for Discontinuing Warfarin/DabigatranContinue in Atrial Fibrillation if:
CHADs2 score of 5 – 6Prior CVAMechanical valve (particularly if
mitral/tricuspid position)Continue in VTE if:
VTE in last 3 – 6 months History of recurrent VTEVTE with concomitant malignancy (LMWH is
probably first choice as more efficacious)
![Page 18: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/18.jpg)
Dementia medicationsCholinesterase inhibitors—indicated for mild
to moderate dementiaDonepezil (Aricept®)Rivastigment (Exelon®)Galantamine (Razadyne®)
NMDA receptor antagonist—indicated for moderate to severe dementiaMemantine (Namenda®)
![Page 19: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/19.jpg)
Recommendations for discontinuing dementia medicationsPatients in hospice have dementia more
severe than what drug therapy is indicated for
Expensive$200 – 300/month
May be safer to taperCan see more agitation when medication
discontinuedAlternative, cheaper agents for agitation exist
![Page 20: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/20.jpg)
Osteoporosis MedicationsBisphosphonates
Alendronate (Fosamax ®)Risedronate (Actonel®)Ibandronate (Boniva®)Zoledronic Acid (Reclast®)
Teriperatide (Forteo®)≈ $1000/month
![Page 21: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/21.jpg)
Recommendations for discontinuing osteoporosis medicationsContinue bisphosphonates if:
Known metastatic bone diseaseBreast CA, prostate CA or multiple myelomaPaget’s disease of bone (usually high dose)
Discontinue all other osteoporosis medications:TeriperatideDenosumab (Prolia®)CalcitriolCalcitonin?
![Page 22: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/22.jpg)
Drugs to taper if discontinuingAnti-epileptic medicationsOpioidsAnti-depressantsBenzodiazepinesBeta blockersClonidineCorticosteroids
![Page 23: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/23.jpg)
Barriers to discontinuing medicationsPsychological attachmentConcern that discontinuation implies “giving
up”Uncertain of risks with discontinuationPhysical dependenceClinical inertiaPoor communication
![Page 24: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/24.jpg)
Elizabeth N.Elizabeth N. is a 90 y/o woman who has been referred
to hospice following three hospitalizations in the last 2 months for refractory congestive heart failure. She is short of breath with minimal exertion. She has decided that she does not want to be readmitted to the hospital.
Her current medications include furosemide, lisinopril, carvedilol, spironolactone, warfarin, simvastatin, ASA, alendronate and morphine sulfate PRN.
Would it be appropriate to discontinue any of these medications?
![Page 25: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/25.jpg)
Elizabeth N.Discontinue:
WarfarinSimvastatinAlendronate
Continue:LisinoprilCarvedilolSpironolactoneASAMorphine sulfate
![Page 26: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/26.jpg)
David E.David E. is a 53 y/o referred to hospice with newly
diagnosed metastatic pancreatic cancer. At the time of presentation his tumor was non-resectable due to hepatic metastases and a biliary stent was placed percutaneously because of obstructive jaundice. His comorbidities include COPD, BPH and a DVT which occurred during his recent hospitalization.
His current medications include warfarin, tamsulosin, ipratropium, salmeterol/fluticasone, saw palmetto, iron sulfate and oral meperidine for pain.
![Page 27: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/27.jpg)
David E.Discontinue
Saw palmettoFeSO4Meperidine (substitute alternative opioid)
ContinueTamsulosinIpratropiumSalmeterol/fluticasoneWarfarin (consider change to LMWH)
![Page 28: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/28.jpg)
Lola P.Lola P. is a 89 y/o woman with endstage
dementia who has been referred to hospice. She is nonambulatory, nonverbal, is unable to assist in any activities of daily living. She is incontinent and has contractures of her hands and knees. Her comorbidities include COPD, CAD (with prior MI and CHF), HTN and hypercholesterolemia.
Her current medications include furosemide, lisinopril, salmeterol/fluticasone, simvastatin, alendronate, vitamin D, calcium carbonate, omeprazole, donepezil, memantine and aspirin
![Page 29: Jennifer Good MD Hospice Medical Director, Home Nursing Agency Altoona, Pennsylvania Mary Mihalyo BS, PharmD, RPh Duquesne University Pittsburgh, Pennsylvania](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649d8a5503460f94a70a1e/html5/thumbnails/29.jpg)
Lola P.Discontinue
Vitamin DCalcium carbonateSalmeterol/fluticasone (substitute PRN nebulized
beta agonist)DonepazilMemantineSimvastatinAlendronate
ContinueFurosemideLisinopril(? Omeprazole)